Thu, May 8, 8:11 PM (15 days ago)
**Tyra Biosciences, Inc. (TYRA) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** No revenue generated; Tyra Biosciences is a clinical-stage biotech company focused on research and development. - **Net Loss:** $28.1 million for Q1 2025, up from $18.2 million in Q1 2024, due to increased R&D and operational expenses. - **Cash Position:** $318.9 million in cash, cash equivalents, and marketable securities as of March 31, 2025. - **Operating Expenses:** Total operating expenses were $31.9 million, up from $22.3 million in Q1 2024. - **R&D Expenses:** $25.0 million, up from $17.2 million, driven by clinical trial start-up activities and headcount growth. - **G&A Expenses:** $6.9 million, up from $5.1 million, primarily due to increased personnel costs. - **Profit Margins:** Not applicable due to ongoing R&D and no revenue generation. - **Cash Flow:** Net cash used in operating activities was $25.5 million, up from $22.0 million in Q1 2024. Net cash provided by investing activities was $32.0 million, up from $18.1 million, primarily due to maturities of marketable securities. **Earnings Changes and Trends:** - **Earnings Per Share (EPS):** Basic and diluted net loss per share was $0.47, up from $0.35 in Q1 2024. - **Trends:** Increased expenses due to clinical trial activities and headcount growth. The company expects to continue incurring significant expenses and operating losses. **Future Operations and Uncertainties:** - **Funding:** Tyra Biosciences believes its current cash position will be sufficient to fund operations through at least 2027. However, future funding may be required through equity offerings, debt financings, or collaborations. - **Clinical Trials:** The company has several ongoing and planned clinical trials for its product candidates, including TYRA-300, TYRA-200, and TYRA-430. - **Regulatory Approval:** The company has not yet generated revenue and does not expect to do so until it successfully completes the development of and obtains regulatory approval for its product candidates. - **Market Risks:** The company is exposed to market risks, including interest rate risk, foreign currency exchange risk, and inflation risk. However, there have been no material changes in market risk from the previous year. **Key Takeaways:** - Tyra Biosciences is a clinical-stage biotech company with no revenue and significant operating losses. - The company's financial health is supported by its cash position and planned clinical trials. - Future operations and financial performance will depend on the success of clinical trials, regulatory approvals, and potential collaborations or financings.